Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 154 Breast Neoplasms 117 Carcinoma, Non-Small-Cell Lung 66 Triple Negative Breast Neoplasms 45 Neoplasm Metastasis 45 Neoplasms 44 Lung Neoplasms 26 Ovarian Neoplasms 25 Squamous Cell Carcinoma of Head and Neck 24 Stomach Neoplasms 23 Melanoma 16 Esophageal Neoplasms 16 Adenocarcinoma 15 Head and Neck Neoplasms 13 Recurrence 12 Esophageal Squamous Cell Carcinoma 12 Cholangiocarcinoma 12 Sarcoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Small Cell Lung Carcinoma 10 Fallopian Tube Neoplasms 10 Uterine Cervical Neoplasms 9 Urinary Bladder Neoplasms 8 Pancreatic Adenocarcinoma 8 Colorectal Neoplasms 8 Prostatic Neoplasms 7 Inflammatory Breast Neoplasms 7 Carcinoma, Pancreatic Ductal 7 Breast Neoplasms, Male 7 Biliary Tract Neoplasms 7

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Albumin-Bound Paclitaxel × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡